drugset / Trial / NCT00350831
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of the KIT inhibitor XL820 when given orally daily to adults with advanced solid tumors.
Timeline
- Start
- 2006-07
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XL820 | Unknown | — | Oral |